Abstract: The invention described herein provides compositions and methods for treating or preventing Helicobacter pylori infection.

Abstract: Embodiments of the inventions provide crystals of AmiS/Urel superfamily, urea-channel protein, methods of crystallizing such protein, and crystalline structures of such protein obtained by x-ray diffraction. Embodiments of the invention provide methods of identifying or designing antagonists and/or agonists of AmiS/Urel-superfamily, urea-channel protein based on crystalline structures thereof. In certain embodiments of the invention, the AmiS/Urel-superfamily, urea-channel protein is the Helicobacter pylori protein, HpUreI.

Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a prostate cancer, a benign prostatic hyperplasia, and/or neovascularization or pathological angiogenesis associated with a cancer in a mammal using such TVEMP compositions.

Abstract: The compounds of formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability in plasma and improved bioavailability.

Abstract: A system and method for supporting a wave-energy generation device that features an adaptive floating platform, which under computer control, can autonomously adjust at least one of its design elements in order to increase or decrease the responsiveness of the floating wave-energy support system to varying wave-energy conditions. By, thereby, being able to tune the wave-energy support platform for varying wave conditions, a greater amount of power can be produced from a wave energy conversion generator selected to be compatible with the adaptive floating platform.

Abstract: The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability in plasma and improved bioavailability.

Abstract: A new administration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.

Abstract: The present invention relates to a compound comprising a toxin linked to a translocator. Non-limiting examples of toxins of the present invention are botulinum toxin, butyricum toxin, tetani toxins and the light chains thereof. In some embodiments, the translocator of the present invention comprises a protein transduction domain.

Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

Abstract: A new administration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.

Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

Abstract: The present invention relates to a compound comprising a toxin linked to a translocator. Non-limiting examples of toxins of the present invention are botulimum toxin, butyricum toxin, tetani toxins and the light chains thereof. In some embodiments, the translocator of the present invention comprises a protein transduction domain.

Abstract: Prodrugs of proton pump inhibitors of Formulas 1 through 4, where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.

Abstract: Prodrugs of proton pump inhibitors of Formulas 1 through 4, where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.

Abstract: A new adminstration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.

Abstract: Prodrugs of proton pump inhibitors of Formulas 1 through 4, where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.

Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

Abstract: Three proteins are obtained from H. pylori bacteria each of which has regions which act as antigens specific to H. pylori. The proteins are isolated, identified and designated HP1, HP2 and HP3 with respective molecular weights of 32 kd, 30 kd, 23 kd. These are expressed as recombinant proteins in E. coli, purified and individually spotted onto a membrane filter. An assay, a method and a kit is developed utilizing a combination of the three proteins to detect the presence of antibodies to H. pylori in human sera. The method of detection is quantified and suitable for monitoring both the infection and the eradication of H. pylori bacteria by drug therapy of human patients infected by these bacteria.

Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

Abstract: Inhibitors of the alpha carbonic anhydrase inhibitors are administered to treat H. pylori infection in the mammalian, including human, stomach. The inhibitors are administered to mammals, including humans, in an amount that results in 4×10−4 to 4×10−9 Molar concentration of the drug in the stomach because this concentration range is lethal to the H. pylori bacteria.